Skinvisible, Inc. Files 8-K
Ticker: SKVI · Form: 8-K · Filed: May 29, 2024 · CIK: 1085277
| Field | Detail |
|---|---|
| Company | Skinvisible, Inc. (SKVI) |
| Form Type | 8-K |
| Filed Date | May 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-disclosure, financial-statements
Related Tickers: SKVI
TL;DR
SKVI filed an 8-K on 5/29 for Reg FD disclosure & financials.
AI Summary
Skinvisible, Inc. filed an 8-K on May 29, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or details about the nature of the disclosure.
Why It Matters
This 8-K filing indicates that Skinvisible, Inc. has made a regulatory disclosure and submitted financial statements, which could contain important updates for investors.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not appear to contain negative news or significant financial events.
Key Players & Entities
- Skinvisible, Inc. (company) — Registrant
- May 29, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 702-433-7154 (phone_number) — Registrant's telephone number
- 6320 South Sandhill Road Suite 9, Las Vegas, NV 89120 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is May 29, 2024.
In which state is Skinvisible, Inc. incorporated?
Skinvisible, Inc. is incorporated in Nevada.
What is the principal executive office address for Skinvisible, Inc.?
The principal executive office address is 6320 South Sandhill Road Suite 9, Las Vegas, NV 89120.
What is the telephone number for Skinvisible, Inc.?
The telephone number for Skinvisible, Inc. is 702-433-7154.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-05-29 13:35:22
Filing Documents
- skvi8k052924.htm (8-K) — 22KB
- ex99_1.htm (EX-99.1) — 11KB
- image_001.jpg (GRAPHIC) — 5KB
- 0001663577-24-000143.txt ( ) — 207KB
- skvi-20240529.xsd (EX-101.SCH) — 3KB
- skvi-20240529_lab.xml (EX-101.LAB) — 33KB
- skvi-20240529_pre.xml (EX-101.PRE) — 22KB
- skvi8k052924_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On May 29, 2024, we issued a press release concerning the filing of our Provisional Patent Application with the US Patent & Trademark Office entitled "Transdermal Delivery Composition for Delivery of CB-1 Receptor Antagonists and/or GLP-1 Receptor Agonists, and Method of Delivery," covering formulations that leverage our proprietary delivery technology Invisicare for the transdermal administration of obesity drugs, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. SECTION 9 – Financial
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated May 29, 2024 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Skinvisible, Inc. /s/ Terry Howlett Terry Howlett Chief Executive Officer Date: May 29, 2024 3